苏拉明抑制SARS-CoV-2核酸蛋白基因组包装功能
Irene Boniardi1, Angela Corona2, Jerome Basquin3
1Department of Molecular Structural Biology, Max Planck Institute of Biochemistry, Martinsried 82152, Germany.
Virus research
|September 13, 2023
概括
药物Suramin通过阻断病毒基因组包装来抑制SARS-CoV-2的复制. 这种古老的药物显示出潜力,可以作为开发新型COVID-19抗病毒药物的起点,以对抗抗性变种.
科学领域:
- 病毒学 病毒学
- 药物发现 药物发现 药物发现
- 分子生物学分子生物学
背景情况:
- 由于SARS-CoV-2变种,COVID-19大流行仍在持续,需要新的抗病毒药物.
- 在SARS-CoV-2核体 (N) 蛋白对于病毒包装和免疫逃避至关重要.
- 针对新型SARS-CoV-2蛋白质是开发有效的COVID-19治疗方法的优先事项.
研究的目的:
- 调查Suramin作为对SARS-CoV-2的潜在抗病毒剂.
- 在SARS-CoV-2蛋白质组中识别治疗点.
- 了解Suramin抑制SARS-CoV-2复制的机制. 了解Suramin抑制SARS-CoV-2复制的机制.
主要方法:
- 微型差异扫描光测量和微量热泳以评估Suramin-N蛋白相互作用.
- 分子对接以预测Suramin结合部位.
- 用电子显微镜观察Suramin对RNP复合体形成的影响.
- 基于细胞的测试来评估Suramin的抗病毒活性和对IFN-I产生的影响.
主要成果:
- 苏拉明与SARS-CoV-2 N蛋白的N端域 (NTD) 和C端域 (CTD) 结合,具有低微分子亲和力.
- 苏拉明抑制了N蛋白的RNA结合功能,并防止了RNP复合体在体外形成.
- 苏拉明可以减少细胞培养中的病毒细胞病变效应,并部分恢复IFN-I的产生.
- 分子对接确定了N蛋白上潜在的可用药物的RNA结合部位.
结论:
- 苏拉明通过破坏病毒基因组包装,有效地抑制SARS-CoV-2复制.
- 药物Suramin作为设计新型COVID-19抗病毒药物的有希望的化合物.
- 针对SARS-CoV-2 N蛋白质提供了一种可行的策略,用于打击当前和未来的病毒威胁.
相关概念视频
siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
Eukaryotic Transcription Inhibitors
9.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.9K
Subviral Agents
41
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
41
Leaky Scanning
5.2K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.2K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


